Economic Times | European Setback For Novartis Heart Failure Drug Forbes The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended against giving market approval to serelaxin (Reasanz) for the treatment of acute heart failure. The recommendation is based largely on the ... Novartis still sees heart failure blockbuster after EU blow UPDATE 2-Novartis still sees heart failure blockbuster after EU blow Novartis to request re-examination of serelaxin (RLX030) in acute heart ... |
